Genetic Technologies Limited (ADR) (NASDAQ:GENE)

CAPS Rating: 1 out of 5

A biotechnology company, pursuing commercial opportunities in: out-licensing its non-coding patents globally; expanding genetic service-testing business in the Asia-Pacific Region; & supporting research projects in which it is already involved.

Results 1 - 6 of 6

Recs

0
Member Avatar pchop12316 (85.46) Submitted: 8/22/2014 10:21:44 AM : Underperform Start Price: $0.65 GENE Score: -1.08

continuing decline likely

Recs

0
Member Avatar red1582 (< 20) Submitted: 11/16/2012 11:52:49 AM : Underperform Start Price: $2.58 GENE Score: +121.81

100% Sell Signal
Gaped Down

Recs

1
Member Avatar MarkSmithJr777 (< 20) Submitted: 7/20/2011 7:34:41 PM : Underperform Start Price: $7.70 GENE Score: +140.62

Coming down

Recs

0
Member Avatar ferdicemara (< 20) Submitted: 5/15/2011 11:38:11 AM : Outperform Start Price: $7.73 GENE Score: -141.72

success

Recs

0
Member Avatar Lifeguru (65.07) Submitted: 4/9/2007 5:00:09 PM : Underperform Start Price: $7.10 GENE Score: +137.70

Junk

Recs

0
Member Avatar ctolbert (80.29) Submitted: 4/6/2007 7:39:22 PM : Underperform Start Price: $5.91 GENE Score: +135.51

Genetics companies are a hard sell and are too susceptible to market news to bank on.

Results 1 - 6 of 6

Featured Broker Partners


Advertisement